This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Hartwig Medical Foundation | |
|---|---|
| Name | Hartwig Medical Foundation |
| Formation | 2017 |
| Type | Non-profit foundation |
| Headquarters | Netherlands |
| Focus | Cancer genomics, diagnostic oncology, data sharing |
Hartwig Medical Foundation Hartwig Medical Foundation is a Dutch non-profit organization focused on centralized cancer genomic data collection, analysis, and sharing to support precision oncology, translational research, and clinical decision-making. Founded with collaborations among academic hospitals, research institutes, and industry partners, the foundation aggregates whole-genome sequencing data, clinical annotations, and biobanked material to accelerate discovery across oncology, pathology, and bioinformatics. Its networked operations intersect with major European research infrastructures, national health systems, and global consortia.
The foundation emerged from partnerships among Netherlands Cancer Institute, University Medical Center Utrecht, Amsterdam UMC, Erasmus MC, and stakeholders such as Philips (company), Illumina, Thermo Fisher Scientific, Foundation Medicine and Genomics England. Early programs aligned with initiatives like Cancer Moonshot, European Union Horizon 2020, Wellcome Trust collaborations and national projects including ZonMw funding. Key milestones involved integration with biobanks such as Biobanking and Biomolecular Resources Research Infrastructure and adoption of standards promoted by Global Alliance for Genomics and Health, European Genome-phenome Archive, and EuroBioBank. The project timeline reflects influence from legacy cohorts at Netherlands Comprehensive Cancer Organisation and policy dialogues involving Ministry of Health, Welfare and Sport (Netherlands) and advisory groups including Health Council of the Netherlands.
The foundation’s mission centers on harmonizing clinical whole-genome sequencing to support precision medicine for oncology patients, enabling translational research by linking genomic profiles to treatment outcomes, tumor biology, and drug response. Objectives include establishing interoperable data platforms compatible with FAIR principles, supporting multicenter trials like those run by European Organisation for Research and Treatment of Cancer and facilitating biomarker discovery relevant to regulators such as European Medicines Agency and payers like Nederlands Zorginstituut.
Governance comprises a supervisory board with representatives from academic centers—including Leiden University Medical Center, Radboud University Medical Center, Maastricht University Medical Center+—industry partners such as Roche and philanthropic stakeholders like Oncode Institute. Funding streams combine competitive grants from entities such as Netherlands Organisation for Scientific Research, translational grants from Dutch Cancer Society, service contracts with biotechnology firms like Qiagen, and charitable donations from foundations modeled after Wellcome Trust and Bill & Melinda Gates Foundation approaches. Corporate collaborations are governed by agreements consistent with standards from European Federation of Pharmaceutical Industries and Associations.
Core activities include centralized processing of tumor and normal specimens, clinical-grade whole-genome sequencing services often interfacing with platforms by Illumina and PacBio, and computational analyses leveraging pipelines developed with tools inspired by GATK, SAMtools, CIViC annotation, OncoKB and mutation callers referenced from COSMIC. Services extend to tumor board support in hospitals like Amsterdam UMC (VUmc), molecular tumor board data feeds to cancer centers including NKI-AVL, clinical trial matching analogous to platforms used by ASCO and providing data resources for projects involving European Reference Networks.
The foundation maintains a secure data infrastructure integrating biobanked specimens with whole-genome sequence files, clinical metadata, radiology annotations, and pathology slides digitized with scanners from Leica Microsystems and Hamamatsu. Data governance aligns with repositories like European Genome-phenome Archive and interoperates using standards from HL7 FHIR, CDISC, and ontologies promoted by Human Phenotype Ontology and Global Alliance for Genomics and Health. Physical biospecimens are stored following best practices from ISBER and linked to national biobanks such as Dutch National Tissue Bank.
The foundation has contributed to studies on mutational signatures building on frameworks by Alexandrov et al. and to pan-cancer analyses comparable to efforts by The Cancer Genome Atlas and International Cancer Genome Consortium. Collaborations include academic groups at Cambridge University, University of Oxford, Massachusetts Institute of Technology, and industry partners like Novartis and Bayer for drug-response studies. Outputs have informed variant interpretation initiatives such as ClinVar submissions, enabled classifier development using methods from The Alan Turing Institute, and supported clinical trials run by European Society for Medical Oncology affiliates.
Ethical oversight involves institutional review boards at participating centers including Amsterdam UMC Ethics Review Board, compliance with national law such as Dutch Medical Treatment Contracts Act interpretations, and alignment with General Data Protection Regulation standards. Consent frameworks reflect models used by Genomics England and governance principles advocated by Nuffield Council on Bioethics and Royal Netherlands Academy of Arts and Sciences. Data access committees evaluate requests in tandem with privacy-preserving technologies inspired by work at Oxford Privacy Research Group and collaborations with legal scholars at Leiden University and Utrecht University.
Category:Biobanks Category:Cancer research organizations Category:Genomics